CCI-779 concentrate formulations
AssigneeWyeth
InventorsJoseph T Rubino, Victoria Siskavich, Maureen M Harrison, Pooja Gandhi
Life of this patent
Estimating the term…
Abstract
This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
Claims13
A CCI-779 cosolvent concentrate for preparing a parenteral formulation upon admixture with a diluent, said concentrate comprising:
- about 1 mg/mL to about 25 mg/mL of CCI-779;
- about 15% w/v to about 60% w/v dehydrated ethanol;
- about 15% w/v to about 60% w/v propylene glycol;
- about 0.01% w/v to about 0.1% w/v of d,1-α-tocopherol;
- and
- about 0.001 to about 0.005% w/v of citric acid.
A CCI-779 cosolvent concentrate for preparing a parenteral formulation upon admixture with a diluent, said concentrate consisting of about 1 to about 25 mg/mL of CCI-779, about 0.01 to 0.1% w/v of d,1-α-tocopherol, up to about 0.1% w/v of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, and about 15 to about 60% w/v of dehydrated ethanol and propylene glycol.
Dependencies are inferred from the claim text.